ProQR Therapeutics (PRQR) EBITDA (2013 - 2026)
ProQR Therapeutics (PRQR) posted EBITDA of -$16.0 million for Q1 2026, down 50.9% sequentially from -$10.6 million in Q4 2025, and down 40.45% YoY from -$26.8 million in Q1 2025.
ProQR Therapeutics (PRQR) EBITDA (2013 - 2026) Analysis & Trends
ProQR Therapeutics has reported EBITDA for 14 years, with the latest figure at -$16.0 million in Q1 2026.
- Quarterly EBITDA fell 40.45% year-over-year to -$16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$53.6 million (down 50.64% YoY) and the FY2025 annual result came in at -$50.6 million, down 55.31% from the prior year.
- EBITDA slipped to -$16.0 million in Q1 2026 per PRQR's latest filing, from -$10.6 million in the prior quarter.
- Over five years, EBITDA peaked at -$3.9 million in Q2 2024 and troughed at -$20.0 million in Q3 2022.
- A 5-year average of -$11.8 million and a median of -$10.8 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2025: EBITDA surged 59.75% in 2023, then plunged 257.65% in 2025.
- Over 5 years, EBITDA stood at -$12.7 million in 2022, then soared by 46.95% to -$6.7 million in 2023, then slumped by 59.73% to -$10.8 million in 2024, then advanced by 1.7% to -$10.6 million in 2025, then slumped by 50.9% to -$16.0 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$16.0 million, -$10.6 million, and -$13.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | -15.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.98 Mn |
| Dec 31, 2025 | -10.59 Mn |
| Sep 30, 2025 | -13.19 Mn |
| Jun 30, 2025 | -13.87 Mn |
| Mar 31, 2025 | -11.38 Mn |
| Dec 31, 2024 | -10.77 Mn |
| Sep 30, 2024 | -9.57 Mn |
| Jun 30, 2024 | -3.88 Mn |
| Mar 31, 2024 | -8.77 Mn |
| Dec 31, 2023 | -6.74 Mn |
| Sep 30, 2023 | -8.05 Mn |
| Jun 30, 2023 | -9.59 Mn |
| Mar 31, 2023 | -10.08 Mn |
| Dec 31, 2022 | -12.71 Mn |
| Sep 30, 2022 | -19.99 Mn |
| Jun 30, 2022 | -16.89 Mn |
| Mar 31, 2022 | -19.13 Mn |
| Dec 31, 2021 | -19.82 Mn |
| Sep 30, 2021 | -17.17 Mn |
| Jun 30, 2021 | -15.90 Mn |